| Neuroendocrine Tumor G2 studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT05773274Phase 2 · recruiting Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial · condition mapped CURATED_BROADER · 20 trials mapped (15 active) | — | — | Digestive System Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375320Phase 3 · active not recruiting Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665739Phase 2 · recruiting Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Lung Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00569127Phase 3 · active not recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01841736Phase 2 · active not recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016855Phase 4 · recruiting Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Digestive System Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03110978Phase 2 · active not recruiting Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Lung Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04339036Phase 2 · recruiting CapTemY90 for Grade 2/3 NET Liver Metastases · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150546Phase 1 · recruiting Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. · condition mapped CURATED_BROADER · 20 trials mapped (15 active) | — | — | Digestive System Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03879694Phase 1 · completed Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Lung Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987176Phase 2 · terminated Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06148636early Phase 1 · active not recruiting A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395402Phase 2 · recruiting 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111509early Phase 1 · active not recruiting A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464122recruiting Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855095Phase 2/Phase 3 · recruiting Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06472388Phase 2 · recruiting Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors · condition mapped ALIAS · 20 trials mapped (15 active) | — | — | Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06080204NA · completed Real-world Study on Adjuvant Octreotide Therapy in pNETs · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Pancreatic Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02893930Phase 2 · completed Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Pancreatic Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01229943Phase 2 · completed Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 20 trials mapped (15 active) | — | — | Pancreatic Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |